TUMOR BOARD 15/09/14 DR. C. MWANIKI.

Slides:



Advertisements
Similar presentations
MGUS (interpreting the test you didnt order) Family Medicine Review Course 2011 Christian Cable, MD, FACP.
Advertisements

Multiple Myeloma Serena Ezzeddine Morning Report May 30, 2009.
Prepared by: Tristan Villanueva Arcibal BSN-RN Presented on: July 16, 2013 A CASE PRESENTATION OF A PATIENT WITH DIABETIC KETOACIDOCIS (DKA)
Neel Bhalala (2009) Sofia Medical University. Background  Erythropoiesis-stimulating agents are man-made versions of a natural protein known as erythropoietin.
Show and Tell FIRM B - RED. Our team Dr. Clarke & Dr. Vargas Shinoj & Arvind Jacob & Muneeza Chloe, Lauren & Njiye.
Treatment of Acute Pulmonary Embolism
PLASMA CELL DYSCRASIAS Monoclonal gammopathy of uncertain significance (MGUS)  Idiopathic  Associated with other diseases (autoimmune, infectious, non-heme.
Bleeding and Thrombosis in Children Alice J. Cohen, M.D. Newark Beth Israel Medical Center.
Vital Signs Chapter 15. Vital Signs Various factors that provide information about the basic body conditions of the patient 4 Main Vital Signs 1.Temperature.
Objectives To introduce the terminology used in describing the plasma cells neoplasm. To explain the physiology of the normal cells & the pathological.
OncoTracker James Berenson, MD President and CEO November 2014.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision of Prof.
DPT 732 SPRING 2009 S. SCHERER Deep Vein Thrombosis.
NRS 220 Alterations in Cellular Metabolism.  MDS is a group of disorders that is caused by the formation of abnormal cells in the bone marrow which can.
Dr. Khalid Al-Zahrani Assistant Professor of Plastic Surgery Course Organiser, Surg. 351 Department of Surgery.
Introduction to Cancer
Multiple Myeloma Definition:
JCM--OSCE KWH 3 August Question 1 A 45 years old man with good past health complained of severe sore throat and odynophagia for 2 days. He had low.
JCM OSCE Questions Caritas Medical Centre 3 June, 2015.
Case Report Pneumology Dr. David Tran A&E, FVHospital Medical meeting September 28 th, 2011.
By: Jameson King and Tyler Holloway
Multiple Myeloma Definition: B-cell malignancy characterised by abnormal proliferation of plasma cells able to produce a monoclonal immunoglobulin (M protein)
Plasma cell Disorders S. Sami Kartı, MD, Prof.. Plasma cells  Terminally differentiated cells of B- lymphocyte lineage  Produce antibodies  Normal.
IMMUNOCHEMISTRY PROFILES Dr. Thomas Williams. TESTS DISEASES CASES.
Multiple Myeloma Definition:
Epidemiology 12,000 deaths in United States per year
Case Discussion Dr. Raid Jastania. What is the outcome of inflammation?
Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney Sophina Hissaund FY2.
Treatment Multiple Myeloma. Symptomatic/progressive myeloma: Systemic therapy - to control progression of myeloma Supportive care - to prevent serious.
1 By Dr. Zahoor. Question 1 A 36 year old male patient presents with tiredness, headaches and following is the blood count:  Hb 9.2 g/dl  MCV 109 fl.
Multiple Myeloma Morning Report July 21, 2009 Lindsay Kruska.
Justin A. Crocker.  1 of the monoclonal gammopathies  Neoplastic proliferation of immunoglobulin producing plasma cells (single clone), often resulting.
What is Edema? What are Ulcers? How can Edematous Limbs be treated?
History taking and physical examination. KEY ELEMENTS Introduce yourself,(name and position) Rapport with patient, Beginning start with open ended questions,
Dr. Zahoor 1.  Blood  Plasma  Hematocrit or PCV  Plasma Protein  Erythropoiesis  Anaemia  White Blood Cell (WBC) 2.
Benign prostatic hyperplasia
Dr. Aya M. Serry Renal Failure Renal failure is defined as a significant loss of renal function in both kidneys to the point where less than 10.
Plasma cell dyscrasias. Multiple Myeloma By Dr. Muna A. Kashmool.
Dr Nervana Bayoumy TEXTBOOK OF MEDICAL PHYSIOLOGY GUYTON & HALL 11 TH EDITION UNIT VI CHAPTERS
Jesse C James MD AM Report May 7,  Proliferation of malignant plasma cells and a subsequent overabundance of monoclonal paraprotein  Malignant.
MLAB Hematology Keri Brophy-Martinez
Osteoporosis In Thalassemia Dr Tarek Jawad INT 555.
M. Multiple Myeloma Malignant proliferation of plasma cells. Malignant proliferation of plasma cells. Normal plasma cell form Ig which contain heavy and.
Multiple Myeloma March 13, 2012 Suzanne R. Fanning, DO Greenville Health System.
Chapter 11 Lymphatic System Disorders Mitzy D. Flores, MSN, RN.
A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.
Primary Hyperparathyroidism presenting with Pancreatitis Prof. Aasem Saif MD, MRCP(UK), FRCP(Edin) Workshop A (Calcium and Bone) Friday 25 October 2013.
Kidney Cancer – All You Need to Know!
Case Study Multiple Myeloma.
AN UNUSUAL CASE OF MULTIPLE MYELOMA
Prepared by : IBRAHEEM NIDAL ABU ATWAN SAEED YEHYA HAMMODA
Objectives At the end of this lecture student should be able to:
MULTIPLE MYELOMA (MM) objective: definition of MM Biochemical investigation in Diagnosis.
Plasma Proteins By: Dr Sunita Mittal.
Endocrine and metabolic disorders
Dr WAQAR ASST. PROFESSOR INTERNAL MEDICINE
Clinical approach in Hematology
Case 3 Headache & Slurred Speech Case Presentation
Symptoms and Signs in Hematology/ 2013
Study case 2 leukemia.
Surgical Grand Rounds 12/9/13
Blood Disorders 2.02 Understand the functions and disorders of the circulatory system 1.
Myeloma: Symptoms to diagnosis Can we do better?
Fundamentals of Medicine: Haematology
PARAPRTEINAEMIA and MULTIPLE MYELOMA
Male patient of 52 years old with a two-year history of fatigue and pruritus of his legs , headache . And visual disturbances . He smoked one pack of.
Red Blood Cell Disorders
Bence Jones protein The Bence Jones protein was described by the English physician Henry Bence Jones in 1847 and published in 1848.Henry Bence Jones The.
January 2007 Clinical Cases.
Presentation transcript:

TUMOR BOARD 15/09/14 DR. C. MWANIKI

BIO DATA NAME: M.M AGE: 52 YEARS SEX: MALE

PRESENTING COMPLAINT EASY FATIGABILITY FOR ONE MONTH LOWER BACK PAIN (LONG STANDING)

HISTORY OF PRESENTING COMPLAINT M.M. is a patient with multiple myeloma on follow up in the haemato-oncology clinic. Was well until a month ago when he started experiencing easy fatigability which was gradual in onset He reports a positive history of awareness of heart beats, dizziness, exertional dyspnea, paroxysmal nocturnal dyspnea and on and off bilateral swelling of the lower limbs. Does not report orthopnea. No history of loss of consciousness. No cough/chest pain No hotness of body

Cont… Patient also complains of a longstanding lower back pain. Not radiating to other parts of the body. Persistent. Get relieved when he takes analgesics No history of trauma/ strain to the back.

TREATMENT HISTORY Patient was started on melphalan (12mg od for 4/7) and prednisone (35mg for 4/7) on 4/6/12 which he has been using up to 27/5/14. He was then changed to thalidomide (100mg od) and dexamethasone (40mg weekly) due to failure to respond to therapy. He used thalidomide and dexamethasone up to 4/8/14. Regimen stopped after patient developed neutropenia and deep venous thrombosis. Patient is now on analgesics and on follow up in the anticoagulation clinic- on warfarin.

PAST MEDICAL HISTORY Patient has been hospitalized twice for blood transfusion. First was in 2012 where he received 5 units of blood then early 2014 where he got transfused 2 units. No history of surgery He does not suffer from other chronic illnesses

FAMILY/ SOCIAL HISTORY Patient is married with 2 children He is a teacher. He does not drink/ smoke There is no one with similar illness in the family/ other chronic illness.

SUMMARY M.M. is a 52 year old patient with multiple myeloma presenting with easy fatigability for one month and longstanding lower back pain

GENERAL PHYSICAL EXAM Sick looking man. No signs of wasting Moderate palor No jaundice/cyanosis/lymphadenopathy Pedal edema on both lower limbs- pitting and non tender Not dehydrated Blood pressure 118/80 Pulse rate 80 beats/minute Respiratory rate 18 breathes/minute Temp 35.5 ◦c

Respiratory system: -respiratory rate of 18 bpm -Normal breath sounds Cardiovascular system -blood pressure 118/80 -pulse rate 80 bpm -normal heart sounds Abdomen -no organomegally -not tender

INVESTIGATIONS DATE 21/5/12 2/7/12 5/11/12 20/5/13 26/5/14 4/8/14 8/9/14 WBC 2.75 2.66 3.82 3.44 4.91 5.6 8.7 ANC 2.22 0.93 2.23 2.09 1 2.06 2.4 Hb 5.08 10.78 9.35 8.45 8.65 10.17 7.9 MCV 95.90 87.63 90.34 87.78 94.38 89.65 95 HCT 14.3 32.40 26.63 23.54 25.54 29.88 23.5 PLT 125 40 116 81 76 166 Cr - 97.1 294 272.34 272 PO 1.21 K 4.63 Na 138 Urea 12.21

Bone marrow Apirate Done on 6/5/12 ( Nairobi hopital) Upper normal cellularity marrow. M:E ratio of 3:1 Plasmacytosis is present making 35-40% of nucleated cells with dysplastic forms Lymphoid cells not increased Features of myelomatosis.

Repeat BMA Done on 26/5/14 (Moi teaching and referral hospital) Increased cellularity M:E ratio- not given Erythropoiesis- few normoblasts Myelopoiesis- Reduced Megakaryopoiesis- Few noted Lymphocytes- Normal Plasma cells- Increase in neoplastic plasma cells. More than 90% nucleated cells Features of relapse of plasma cell myeloma

Serum Protein electrophoresis Done on 25/5/12(Lancet) S alpha 1 globulin- 5g/L S alpha 2 globulin 10g/L S beta 1 globulin 3g/L S beta 2 globulin 4g/L S gamma globulin 9g/L S ‘M’ component globulin 10g/L*elevated

Repeat SPEP Done on 18/8/14(Lancet) S alpha 1 globulin- 8g/L *elevated S beta 1 globulin 5g/L S beta 2 globulin 3g/L S gamma globulin 6g/L S ‘M’ component globulin 9g/L *elevated

Current management Analgesics for pain Warfarin for DVT Palliative team on board

discussion Multiple myeloma is a type of cancer that starts in the plasma cells in the bone marrow In M.M. Serum Protein electrophoresis which usually shows elevated ‘M’ component Its more common in men and Africans are affected twice as much compared to other races M.M. affects many organs. Commonly causes: -Elevated Calcium level (osteoclastic activity from over expression of receptor activator for RANKL), -Renal failure( excessive production of immunoglobulins and light chains, nephrocalcinosis and amyloidosis) -Anemia (infiltration into the bone marrow) -Bone lessions

Punched out lessions are normally seen on skull xray and extensive lytic lessions in bone scan Related conditions include solitary plasmacytoma,plasma cell dyscrasia, and POEMS syndrome. Staging (I-III) -International staging system ( b2 microglobulin & albumin) -Durie salmon staging system (Hb, Calcium, Skeletal survey,Serum paraproteins levels-IgG,IgA and Urinary light chain excretion)

Issues How long should it take before we change from one regimen to another? Is it possible to re- treat with the agents we started with i.e melphalan/thalidomide.how effective will that be? at this stage, is there a role for third line agents like Linolinamide/ Bortezumab. Availability of drugs/feasibility? Generally, we have had poor outcomes in multiple myeloma patients in the hospital, what is it that we could be doing wrong?